ADAMTS13 and myocardial infarction: As well as the treatment of stroke 41 and myocardial infarction 42, the use of recombinant ADAMTS‐13 as a replacement therapy in acquired TTP 47 and the possibility of gene therapies to overcome ADAMTS‐13 deficiency 48 are also being investigated.